CD BioGlyco is experienced in the development of Glycosphingolipid Inhibitors. GCS glycosylates ceramide to glucose ceramide, thereby reducing the pro-apoptotic effects of ceramide. GCS is overexpressed in a variety of drug-resistant cancer cells. The use of GCS inhibitors as a way to block ceramide glycosylation is expected to provide new ideas for cancer therapy research. Several GCS Inhibitors have been developed. Based on published reports and our extensive experience in Glycosylation Inhibitor Development, we offer multi-faceted GCS Inhibitor development services.
Fig.1 Directions for GCS inhibitor development. (CD BioGlyco)
Technology: High-throughput screening systems
Journal: Journal of Neurochemistry
Results: In this study, a high-throughput screening system was constructed for the study of GCS inhibitors. A novel potent inhibitor, T-036, was successfully identified. It has a different chemical structure from the reported GCS substrate mimetic inhibitors and does not contain aliphatic amine moiety. It was detected to achieve inhibition by non-competitive binding to UDP-glucose. The inhibitory ability of T-036 was further verified by mouse experiments.
Fig.2 Chemical structure of T-036. (Fujii, et al., 2021)
At CD BioGlyco, our glycosylation inhibitor development process keeps up with scientific developments and is constantly updated. We have an experienced research team in inhibitor development to provide high-quality and reliable inhibitor development services. Please feel free to contact us to learn more about GCS inhibitor development. Our researchers will get back to you as soon as possible.